Improved quality control of [177Lu]Lu-PSMA I&T

[1]  J. Nonnekens,et al.  Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [177Lu]Lu-PSMA , 2022, EJNMMI Radiopharmacy and Chemistry.

[2]  E. Aalbersberg,et al.  Quality control of [177Lu]Lu-PSMA preparations using HPLC: effect of sample composition and ligand on recovery , 2022, EJNMMI Radiopharmacy and Chemistry.

[3]  M. Stockler,et al.  177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy , 2022, The Journal of Nuclear Medicine.

[4]  S. Severi,et al.  Production and Quality Control of [177Lu]Lu-PSMA-I&T: Development of an Investigational Medicinal Product Dossier for Clinical Trials , 2022, Molecules.

[5]  R. Lim,et al.  Stability Matters: Radiochemical Stability of Therapeutic Radiopharmaceutical 177Lu-PSMA I&T , 2022, The Journal of Nuclear Medicine Technology.

[6]  A. Buck,et al.  Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [177Lu]Lu-PSMA I&T during long-term follow-up , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[7]  P. Bedouch,et al.  Development and Validation of Analytical Methods for Radiochemical Purity of 177Lu-PSMA-1 , 2022, Pharmaceuticals.

[8]  R. Jia,et al.  177Lu-PSMA-I&T Radioligand Therapy for Treating Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Study in East Asians , 2022, Frontiers in Oncology.

[9]  A. Buck,et al.  Matched-pair analysis of [177Lu]Lu-PSMA I&T and [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  Xiaoyuan Chen,et al.  Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA I&T and 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry , 2021, The Journal of Nuclear Medicine.

[11]  Johannes Notni.  PSMA-Targeted Therapeutics: A Tale About Law and Economics , 2021, The Journal of Nuclear Medicine.

[12]  C. Decristoforo,et al.  Development and validation of the HPLC method for quality control of radiolabelled DOTA-TATE and DOTA-TOC preparations. , 2020, Nuclear medicine and biology.

[13]  Nic Gillings,et al.  EANM guideline on the validation of analytical methods for radiopharmaceuticals , 2020, EJNMMI Radiopharmacy and Chemistry.

[14]  M. Schwaiger,et al.  Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate Cancer. , 2019, European urology.

[15]  G. Glatting,et al.  Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides , 2016, PloS one.

[16]  P. Erba,et al.  From preclinical development to clinical application: Kit formulation for radiolabelling the minigastrin analogue CP04 with In-111 for a first-in-human clinical trial , 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[17]  Tim Holland-Letz,et al.  The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions , 2015, The Journal of Nuclear Medicine.

[18]  Michael Lassmann,et al.  68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies , 2015, The Journal of Nuclear Medicine.

[19]  M. Schwaiger,et al.  Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer , 2014, EJNMMI Research.

[20]  R. Schibli,et al.  Identification, characterization and suppression of side-products formed during the synthesis of high dose ⁶⁸Ga-DOTA-TATE. , 2013, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[21]  T. Holland-Letz,et al.  PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  Roland Haubner,et al.  Radiolabelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system , 2011, Nuclear medicine communications.